DIANA

• Kraj:Polska
• : Język.:polski
• : Utworzony.: 30-12-17
• : Ostatnie Logowanie.: 16-03-22

×

: Kontakt.

: Imię.

: E-mail.

: Wiadomość.

Proszę zamienić znaczniki %d na własne liczby

: Dodaj.

Wiadomość nie może być pusta!

Wiadomość zostanie przetłumaczona po wysłaniu (jeżeli środki są wystarczające)

: Captcha. Kod Ochronny.

Załączniki:

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

: Wybierz: : Edycja. : Usuń.

Ilość dopuszczalnych plików: 5

JPEG, JPG, PNG, GIF, DOC, PDF, ZIP, RAR, TAR, HTML, SWF, TXT, XLS, DOCX, XLSX : lub : ODT : tylko formaty:.

: Maksymalny rozmiar pliku. 3MB.

: Wyślij Wiadomość.

дзяржаўна-прыватнае партнёрства, Apeiron, Iktos, супрацьвірусныя прэпараты BioNTech, moderna, curevac, covid-19, коронавірус, вакцына:

: Opis.: BioNTech, moderna, curevac, covid-19, коронавірус, вакцына: 20200320AD BTM Innovations, дзяржаўна-прыватнае партнёрства, Apeiron, SRI International, Iktos, супрацьвірусныя прэпараты, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, У сакавіку 16 сакавіка Еўракамісія абвясціла, што прапанавала 80 мільёнаў еўра на падтрымку нямецкай кампаніі CureVac для паскарэння працы над коронавіруснай вакцынай. Гэтая інфармацыя з'яўляецца на наступны дзень пасля таго, як нямецкія ўрадавыя крыніцы заявілі, што адміністрацыя Дональда Трампа шукае спосаб атрымаць доступ да гэтай патэнцыяльнай вакцыны. Ці азначае гэта, што ёсць толькі адна кампанія, якая працуе над такім важным для чалавецтва рашэннем? СААЗ (Сусветная арганізацыя аховы здароўя) публікуе дадзеныя пра 13 такіх кампаній на сваіх сайтах, а база дадзеных Global Data паказвае на 30 устаноў, якія працуюць над гэтай тэмай. Ці ёсць шанцы на хуткае ўрэгуляванне нашых праблем? Д'ябал заўсёды ў дэталях. Афіцыйна існуе толькі адна кампанія - American Moderna, якая прайшла этап клінічнага выпрабавання, дзе вакцына выпрабоўваецца на людзях. Тэсты праводзяцца ў ЗША ў Вашынгтонскім інстытуце даследаванняў здароўя ў Сіэтле. Такое хуткае развіццё патэнцыяльнай вакцыны беспрэцэдэнтна і стала магчымым, таму што навукоўцы маглі выкарыстаць вопыт коронавірусаў, якія выклікалі эпідэмію ВРВІ і MERS. Нягледзячы на рэкордныя працы, нават калі вакцына апынецца бяспечнай і эфектыўнай супраць віруса, яна не будзе даступная як мінімум год. Усе астатнія гульцы, якія хочуць распрацаваць вакцыну супраць коронавируса, знаходзяцца на самай перадавой даклінічнай стадыі. Даклінічны этап - гэта даследаванні ў лабараторыях і на жывёл, якія могуць прывесці да вакцынацыі прыблізна праз паўтара года. Цяжка сказаць, хто выйграе гонку за вакцыну, але самыя вялікія шанцы маюць не стартапы, а буйныя фармацэўтычныя кампаніі. Нямецкая кампанія CureVac супрацоўнічае з дзяржаўнай установай, якая базуецца ў Осла, т.зв. Кааліцыя па падрыхтоўцы да эпідэміі (CEPI). Яны працуюць над вакцынай на аснове мРНК. Як і амерыканскі гіганцкі мРНК Moderna, CureVac хоча даказаць, што мРНК вакцыны будуць распрацаваны і выраблены хутчэй, чым традыцыйныя вакцыны, і мае намер перайсці на I этап клінічных выпрабаванняў у пачатку гэтага лета. Як і CureVac - нямецкая кампанія BioNTech, якая займаецца распрацоўкай вакцын мРНК супраць раку і грыпу - з'яўляецца прадметам патэнцыяльнага партнёрства з фармацэўтычным гігантам Pfizer па распрацоўцы вакцыны супраць віруса Covid19. Санофі і Янсэн супрацоўнічаюць з Амерыканскім прасунутым біямедыцынскім бюро па даследаваннях і распрацоўках (BARDA), а таксама знаходзяцца на даклінічнай стадыі. Шмат меншых праектаў таксама вядзецца. У панядзелак2 7 мільёнаў еўра субсідый у рамках праграмы Horizon2020 былі выдзелены дацкаму дзяржаўна-прыватнаму кансорцыуму: біятэхналагічным кампаніям ExpreS2ion Biotechnologies і AdaptVac. Кансорцыум мае намер запусціць клінічнае выпрабаванне вакцыны фазы I / IIa на працягу 12 месяцаў. Хоць самыя раннія вакцыны могуць знаходзіцца ў даклінічнай фазе да лета, рэгулятары, верагодна, спатрэбяцца ад аднаго да двух гадоў тэставання на чалавеку, каб гарантаваць, што вакцына бяспечная і эфектыўная. Пасля атрымання дазволу кампаніі могуць пачаць вырабляць і распаўсюджваць вакцыну ў камерцыйных маштабах, што таксама займае шмат часу. Такім чынам, свет бачыць ухваленую вакцыну Covid-19 толькі прыблізна ў сярэдзіне 2121 года. Аднак аказваецца, што вакцына - не адзінае выратаванне. Многія кампаніі разлічваюць распрацаваць новыя супрацьвірусныя прэпараты альбо адаптаваць сучасныя эксперыментальныя лекі для барацьбы з новым вірусам. Гэта складаная задача, таму што, у адрозненне ад бактэрый, вірусы хаваюцца ў нашых уласных клетках. Гэта азначае, што лекі, якія спыняюць вірус, часцей дзівяць нашы клеткі, што можа выклікаць пабочныя эфекты. Парыжская кампанія Iktos, якая займаецца вытворчасцю лекаў пры дапамозе штучнага інтэлекту, пачала супрацоўніцтва з амерыканскай хімічнай кампаніяй SRI International. Мэта супрацоўніцтва складаецца ў распрацоўцы новых супрацьвірусных прэпаратаў для лячэння Covid19 і іншых відаў вірусаў. У канцы лютага аўстрыйская біятэхналагічная кампанія Apeiron распачала фазу II пілотнага клінічнага выпрабавання прэпарата-кандыдата супраць Covid-19. Бялковы прэпарат ужо завяршыў даследаванні фазы I і II у лячэнні вострай траўмы лёгкіх і, як чакаецца, дзейнічае, імітуючы бялок, з якім каранавірус звязваецца падчас лёгачнай інвазіі. Таксама існуе мноства праектаў, накіраваных на змяненне выкарыстання дазволеных супрацьвірусных прэпаратаў пры лячэнні Covid-19. Гэта мае перавагу ў тым, што бяспека лекі ўжо вядомая і можа выйсці на рынак хутчэй. Даследчыкі з Гётынгена і Берліна, Германія, у цяперашні час даследуюць патэнцыял камостата мезилата - прэпарата, дазволенага ў Японіі для лячэння панкрэатыту. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 19-11-24

বায়োএনটেক, মডেরেনা, কুরিভ্যাক, কোভিড -১৯, করোনভাইরাস, ভ্যাকসিন:

: Opis.: বায়োএনটেক, মডেরেনা, কুরিভ্যাক, কোভিড -১৯, করোনভাইরাস, ভ্যাকসিন: 20200320AD বিটিএম ইনোভেশনস, পাবলিক-প্রাইভেট পার্টনারশিপ, অ্যাপিওরন, এসআরআই ইন্টারন্যাশনাল, ইক্টোস, অ্যান্টিভাইরাল ড্রাগস, অ্যাডাপ্টভ্যাক, এক্সপ্রেস 2 জৈব প্রযুক্তি, ফাইজার, জ্যানসেন, সানোফি, ১ March ই মার্চ, ইউরোপীয় কমিশন ঘোষণা করেছিল যে করোনোভাইরাস ভ্যাকসিনের কাজকে ত্বরান্বিত করতে জার্মান সংস্থা কুরিভ্যাককে সহায়তা দেওয়ার জন্য ৮০ মিলিয়ন ইউরো সরবরাহ করেছে। জার্মান সরকার সূত্র জানিয়েছে যে ডোনাল্ড ট্রাম্প প্রশাসন এই সম্ভাব্য ভ্যাকসিনের অ্যাক্সেস পাওয়ার উপায় খুঁজছে। এর অর্থ কি এই যে কেবলমাত্র একটি সংস্থাই এমন একটি সমাধান নিয়ে কাজ করছে যা মানবতার পক্ষে এত গুরুত্বপূর্ণ? ডাব্লুএইচও (ওয়ার্ল্ড হেলথ অর্গানাইজেশন) এর ওয়েবসাইটে ১৩ টি সংস্থার ডেটা প্রকাশ করে এবং গ্লোবাল ডেটা ডাটাবেস এই বিষয়টিতে কাজ করা 30 টি প্রতিষ্ঠানকে নির্দেশ করে। তাহলে কি আমাদের সমস্যাগুলির দ্রুত প্রতিকারের কোনও সম্ভাবনা রয়েছে? শয়তান সর্বদা বিশদে থাকে। আনুষ্ঠানিকভাবে, কেবলমাত্র একটি সংস্থা রয়েছে - আমেরিকান মোদার্না - এটি একটি ক্লিনিকাল ট্রায়াল পর্ব পেরিয়ে গেছে যেখানে মানুষের মধ্যে ভ্যাকসিন পরীক্ষা করা হচ্ছে। সিয়াটেলের ওয়াশিংটন ইনস্টিটিউট অফ হেলথ রিসার্চ-এ যুক্তরাষ্ট্রে পরীক্ষা করা হয়। একটি সম্ভাব্য ভ্যাকসিনের এ জাতীয় দ্রুত বিকাশ নজিরবিহীন এবং এটি সম্ভব হয়েছিল কারণ বিজ্ঞানীরা করোনভাইরাসগুলির সাথে অভিজ্ঞতাটি সারস এবং এমআরএস মহামারীর কারণ হিসাবে ব্যবহার করতে পারেন। রেকর্ড ব্রেকিং কাজ সত্ত্বেও, ভ্যাকসিনটি ভাইরাসের বিরুদ্ধে নিরাপদ এবং কার্যকর প্রমাণিত হলেও, এটি কমপক্ষে এক বছরের জন্য উপলব্ধ হবে না। অন্য যে সমস্ত খেলোয়াড় একটি করোনভাইরাস ভ্যাকসিন বিকাশ করতে চান তারা বর্তমানে সবচেয়ে উন্নত প্রাক-প্রকৃতির পর্যায়ে রয়েছে। প্রকৃত পর্যায়টি ল্যাবরেটরি এবং প্রাণীদের গবেষণা যা প্রায় দেড় বছরের মধ্যে কেবল টিকা দিতে পারে। ভ্যাকসিনের প্রতিযোগিতা কে জিতবে তা বলা শক্ত, তবে সবচেয়ে বড় সম্ভাবনা স্টার্ট-আপগুলি নয়, বড় ওষুধ সংস্থাগুলি। জার্মান সংস্থা কুরেভ্যাক তথাকথিত অসলো ভিত্তিক একটি সরকারী প্রতিষ্ঠানের সাথে সহযোগিতা করে মহামারী প্রস্তুতি জন্য কোয়ালিশন (সিইপিআই)। তারা এমআরএনএ ভিত্তিক ভ্যাকসিন নিয়ে কাজ করছে। আমেরিকান জায়ান্ট মডেরেনা এমআরএনএ-র মতো কুরিভ্যাক প্রমাণ করতে চায় যে এমআরএনএ ভ্যাকসিনগুলি গতানুগতিক ভ্যাকসিনগুলির চেয়ে দ্রুত তৈরি এবং প্রস্তুত করা হবে এবং এই গ্রীষ্মের প্রথম দিকে প্রথম পর্যায়ের ক্লিনিকাল ট্রায়ালগুলিতে যাওয়ার ইচ্ছা রয়েছে। কুরিভ্যাকের মতো - জার্মান সংস্থা বায়োএনটেক, যা ক্যান্সার এবং ইনফ্লুয়েঞ্জার জন্য এমআরএনএ ভ্যাকসিন তৈরি করে - ওষুধ জায়ান্ট ফাইজারের সাথে কোভিড ১৯ ভাইরাসের বিরুদ্ধে একটি ভ্যাকসিন তৈরির সম্ভাব্য অংশীদারিত্বের বিষয়। সানোফি এবং জানসেন আমেরিকান বায়োমেডিকাল অ্যাডভান্সড অফিস ফর রিসার্চ অ্যান্ড ডেভেলপমেন্টের (বারদা) সাথে সহযোগিতা করেছেন এবং একটি প্রাক্কলিত পর্যায়েও রয়েছেন। অনেক ছোট প্রকল্পও চলছে। সোমবার2-তে হরিজন 2020 প্রোগ্রামের আওতায় 7 মিলিয়ন ইউএসডি অনুদানের জন্য ডেনিশের পাবলিক-প্রাইভেট কনসোর্টিয়ামকে বরাদ্দ করা হয়েছিল: বায়োটেকনোলজি সংস্থা এক্সপ্রেস 2 বিজন বায়োটেকনোলজিস এবং অ্যাডাপ্টভ্যাক। কনসোর্টিয়ামটি 12 মাসের মধ্যে ভ্যাকসিনের জন্য প্রথম পর্যায় I / IIa ক্লিনিকাল ট্রায়াল চালু করতে চায়। যদিও গ্রীষ্মের মধ্যে প্রথম দিকের ভ্যাকসিনগুলি প্রাক-ক্লিনিকাল পর্যায়ে থাকতে পারে তবে এই ভ্যাকসিনটি নিরাপদ এবং কার্যকর কিনা তা নিশ্চিত করতে নিয়ামকদের সম্ভবত এক থেকে দুই বছরের মানবিক পরীক্ষার প্রয়োজন হবে। অনুমোদনের পরে, সংস্থাগুলি বাণিজ্যিক স্কেলে ভ্যাকসিন উত্পাদন এবং বিতরণ শুরু করতে পারে, এতে দীর্ঘ সময়ও লাগে। সংক্ষেপে, বিশ্ব অনুমোদিত কোভিড -১৯ টি ভ্যাকসিন কেবলমাত্র 2121 সালের মাঝামাঝি সময়ে দেখে। তবে দেখা যাচ্ছে যে ভ্যাকসিনই একমাত্র পরিত্রাণ নয়। অনেক সংস্থা নতুন ভাইরাসের বিরুদ্ধে লড়াই করার জন্য নতুন অ্যান্টিভাইরাল ওষুধ বিকাশ করবে বা বর্তমান পরীক্ষামূলক ওষুধগুলিকে মানিয়ে নেবে বলে আশাবাদী। এটি একটি কঠিন কাজ কারণ ব্যাকটিরিয়াগুলির বিপরীতে ভাইরাসগুলি আমাদের নিজস্ব কোষগুলিতে লুকায়। এর অর্থ হ'ল যে ওষুধগুলি ভাইরাসটি আরও বেশি করে থামায় সেগুলি আমাদের কোষগুলিকে প্রায়শই প্রভাবিত করে, যার ফলে পার্শ্ব প্রতিক্রিয়া হতে পারে। কৃত্রিম বুদ্ধিমত্তার মাধ্যমে ওষুধের উত্পাদন নিয়ে কাজ করা প্যারিসের সংস্থা ইক্টোস আমেরিকান রাসায়নিক সংস্থা এসআরআই ইন্টারন্যাশনালের সাথে সহযোগিতা শুরু করে। সহযোগিতার লক্ষ্য হল কোভিড 19 এবং অন্যান্য ধরণের ভাইরাসের চিকিত্সার জন্য নতুন অ্যান্টিভাইরাল ড্রাগগুলি বিকাশ করা। অস্ট্রিয়ান জৈবপ্রযুক্তি সংস্থা অপিওরন ফেব্রুয়ারির শেষে কোভিড -১৯ এর বিরুদ্ধে প্রার্থী ড্রাগের দ্বিতীয় পর্বের পাইলট ক্লিনিকাল ট্রায়াল শুরু করেছিলেন। প্রোটিন ড্রাগটি তীব্র ফুসফুসের আঘাতের চিকিত্সার জন্য ইতিমধ্যে প্রথম এবং দ্বিতীয় পর্যায়ের অধ্যয়ন সম্পন্ন করেছে এবং ফুসফুসের আক্রমণের সময় যে প্রোটিন দিয়ে করোন ভাইরাস বেঁধেছিল তা নকল করে কাজ করার আশা করা হচ্ছে। কোভিড -19-এর চিকিত্সায় অনুমোদিত অ্যান্টিভাইরাল ওষুধের ব্যবহার পরিবর্তন করার লক্ষ্যেও অনেকগুলি প্রকল্প রয়েছে। এটির সুবিধাটি রয়েছে যে ওষুধের সুরক্ষাটি ইতিমধ্যে জানা গেছে এবং দ্রুত বাজারে পৌঁছতে পারে। জার্মানির গ্যাটিনজেন এবং বার্লিনের গবেষকরা বর্তমানে কমোস্ট্যাট মাইসেলেটের সম্ভাবনাগুলি তদন্ত করছেন - যা অগ্ন্যাশয় রোগের চিকিত্সার জন্য জাপানে অনুমোদিত একটি ওষুধ। http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 19-11-24

modernoa, curevac, covid-19, coronavirus, txertoa: Iktos, droga antiviralak, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,

: Opis.: BioNTech, modernoa, curevac, covid-19, coronavirus, txertoa: 20200320AD BTM Innovations, lankidetza publiko-pribatua, Apeiron, SRI International, Iktos, droga antiviralak, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, Martxoaren 16an, Europako Batzordeak jakinarazi zuen 80 milioi euro eskaini zizkion CureVac enpresa alemaniarrari koronavirusaren txertoa lortzeko lanak azkartzeko. Informazio hau Alemaniako gobernuko iturriek esan zuten Donald Trumpeko administrazioak balizko txertoa eskuratzeko modua bilatzen ari zela. Horrek esan nahi du gizakientzat hain garrantzitsua den irtenbide bat lantzen ari den enpresa bakarra dagoela? OMEk (Osasunaren Mundu Erakundea) horrelako 13 enpresei buruzko datuak argitaratzen ditu bere webguneetan, eta Global Data baseak gai honetan lan egiten duten 30 erakunde adierazten ditu. Gure arazoei erremedio azkarra emateko aukerarik al dago? Deabrua xehetasunetan dago beti. Ofizialki, ez dago txertoa gizakietan probatzen ari den proba klinikoko fase batera igaro den enpresa bakarra - Moderna amerikarra. Probak Estatu Batuetan egiten dira Seattleko Washington Institute of Health Research-en. Txertaketa potentzialaren garapen hori ez da aurrekaririk izan, eta zientzialariek SARS eta MERS epidemiak eragin zituzten koronavirusekin esperientzia baliatu ahal izan zuten. Erregistroak hautsi egin dituen arren, txertoa birusaren aurka segurua eta eraginkorra dela frogatu arren, ez da gutxienez urtebetez egongo eskuragarri. Coronavirus txertoa garatu nahi duten gainerako jokalari guztiak fase prekliniko aurreratuenean daude. Klase preklinikoa laborategi eta animalietan ikerketa da, urte eta erdi inguru txertoa besterik ezin dutela ekarri. Zaila da esatea nork irabazi duen txertoaren lasterketa, baina aukera handienak ez dira start-upak, farmazia enpresa handiak baizik. CureVac konpainia alemaniarrak Oslo izeneko egoitza duen erakunde publiko batekin lankidetzan aritzen da Epidemia prestatzeko koalizioa (CEPI). MRNA oinarritutako txertoa lantzen ari dira. Moderna mRNA erraldoi amerikarra bezala, CureVacek mRNA txertoak ohiko txertoak baino azkarrago garatu eta fabrikatuko direla frogatu nahi du, eta Uda hasieran entsegu klinikoetara joateko asmoa du. CureVac-ek bezala, BioNTech konpainia alemaniarrak, minbiziaren eta gripearen aurkako mRNA txertoak garatzen dituena, Cfid19 birusaren aurkako txertoa garatzeko Pfizer erraldoi farmazeutikoarekin lankidetza potentzialaren gaia da. Sanofi eta Janssen Ikerketa eta Garapenerako Bulego Biomedikoko Estatu Batuetako (BARDA) lankidetzarekin lankidetzan aritzen dira eta fase prekliniko batean daude ere. Proiektu txikiago asko ere abian dira. Astelehenean2 milioi euroko diru-laguntza Horizon2020 programaren barruan Danimarkako partzuergo publiko-pribatuari zuzendu zitzaion: bioteknologiako enpresak ExpreS2ion Biotechnologies eta AdaptVac. Partzuergoak asmoa du txertoari buruzko I / IIa faseko proba klinikoa abiaraztea 12 hilabeteko epean. Lehen txertoa fase preklinikoan egon daitekeen arte uda arte, erregulatzaileek gizakien azterketak egin beharko dituzte bi urtez, txertoa segurua eta eraginkorra dela ziurtatzeko. Onarpena lortu ondoren, enpresek txertoa ekoizten eta banatzen has dezakete merkataritza eskalan, eta horrek ere denbora luzea behar du. Laburbilduz, munduak 2121 erdialdearen inguruan bakarrik ikusten du onartutako Covid-19 txertoa. Hala ere, badirudi txertoa ez dela salbazio bakarra. Enpresa askok espero dute antibiotiko berriak garatzea edo egungo sendagai esperimentalak egokitzea birus berriari aurre egiteko. Lan zaila da, izan ere, bakterioak ez bezala, birusak gure zeluletan ezkutatzen dira. Horrek esan nahi du birusa gelditzen duten sendagaiek maizago eragiten dutela gure zeluletan, eta horrek bigarren mailako efektuak eragin ditzakeela. Inteligentzia artifizialaren bidez drogak ekoizten ari zen Parisko konpainiak SRI International konpainia kimiko estatubatuarrarekin lankidetza hasi zuen. Elkarlanaren helburua Covid19 eta beste birus mota batzuk tratatzeko sendagai antiviralak berriak garatzea da. Apeiron bioteknologiako enpresa austriarrak otsailaren amaieran Covid-19ren aurkako hautagaien aurkako medikuntzaren proba kliniko pilotu bat hasi zuen. Proteina drogak dagoeneko burutu ditu I. eta II Faseko ikerketak biriketako lesio akutuen tratamenduan eta biriken inbasioan koronavirusarekin lotzen den proteina imitatuz funtzionatuko dela espero da. Covid-19 tratamenduan onartutako sendagai antiviralak erabiltzea aldatzera zuzendutako proiektu ugari ere badaude. Horrek abantaila du drogaren segurtasuna jada ezaguna dela eta merkatura azkarrago irits daitekeela. Göttingen eta Berlin-eko (Alemania) ikertzaileek kamostat mesilatoaren potentziala ikertzen ari dira - Japonian homologatutako pankreatita tratatzeko. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 19-11-24

BioNTech, moderna, curevac, covid-19, koronavirus, peyvənd:

: Opis.: BioNTech, moderna, curevac, covid-19, koronavirus, peyvənd: 20200320AD BTM İnnovasiyalar, dövlət-özəl tərəfdaşlıq, Apeiron, SRI International, İktos, antiviral dərmanlar, AdaptVac, ExpreS2ion Biotexnologiyalar, pfizer, janssen, sanofi, Martın 16-da Avropa Komissiyası koronavirus peyvəndi üzərində işlərin sürətləndirilməsi üçün Almaniyanın CureVac şirkətinə dəstək üçün 80 milyon avro təklif etdiyini açıqladı. Bu məlumat, Alman hökumət qaynaqlarından Donald Trump rəhbərliyinin bu potensial peyvəndi əldə etmək üçün bir yol axtardığını söylədiyi gündən bir gün sonra ortaya çıxır. Bu o deməkdir ki, bəşəriyyət üçün bu qədər vacib olan bir həll üzərində çalışan yalnız bir şirkət var? ÜST (Ümumdünya Səhiyyə Təşkilatı) bu cür 13 şirkət haqqında məlumatları veb saytlarında yayımlayır və Qlobal Məlumat Bazası bu mövzuda işləyən 30 qurumu göstərir. Yəni problemlərimizi tez bir zamanda aradan qaldırmaq üçün şanslarınız varmı? Şeytan həmişə detallardadır. Rəsmi olaraq, vaksinin insanlarda sınaqdan keçirildiyi bir klinik sınaq mərhələsindən keçmiş Amerikan Moderna - yalnız bir şirkət var. Testlər ABŞ-da Sietldəki Vaşinqton Sağlamlıq Tədqiqatları İnstitutunda aparılır. Potensial bir peyvəndin belə sürətli inkişafı misli görünməmişdir və alimlər SARS və MERS epidemiyalarına səbəb olan koronaviruslarla təcrübədən istifadə edə bildikləri üçün mümkün olmuşdur. Rekord rekord iş görməsinə baxmayaraq, peyvəndi virusa qarşı etibarlı və effektiv olduğunu sübut etsə də, ən azı bir il mövcud olmayacaq. Koronavirus peyvəndi inkişaf etdirmək istəyən bütün digər oyunçular hazırda ən inkişaf etmiş preklinik mərhələdədirlər. Preklinik mərhələ laboratoriyalarda və heyvanlarda aparılan araşdırmalardan yalnız bir il yarım ərzində peyvənd edilməsinə səbəb ola bilər. Peyvənd uğrunda yarışda kimin qalib gələcəyini söyləmək çətindir, amma ən böyük şanslar yeni başlayanlar deyil, əczaçılıq şirkətləridir. Alman şirkəti CureVac, sözdə Oslo şəhərində yerləşən bir dövlət qurumu ilə əməkdaşlıq edir Epidemiyaya Hazırlıq Koalisiyası (CEPI). Bir mRNA əsaslı bir peyvənd üzərində işləyirlər. Amerikan nəhəngi Moderna mRNA kimi CureVac, mRNA peyvəndlərin ənənəvi vaksinlərdən daha sürətli inkişaf etdiriləcəyini və istehsal olunacağını sübut etmək istəyir və bu yayın əvvəlində I mərhələyə aid klinik sınaqlara getmək niyyətindədir. CureVac kimi - xərçəng və qrip üçün mRNA peyvəndlər hazırlayan Alman şirkəti BioNTech, Covid19 virusuna qarşı bir peyvəndi inkişaf etdirmək üçün dərman nəhəngi Pfizer ilə potensial tərəfdaşlıq mövzusudur. Sanofi və Janssen Amerika Biomedical Advanced Araşdırma və İnkişaf Office (BARDA) ilə əməkdaşlıq edir və preklinik mərhələdədirlər. Bir çox kiçik layihələr də davam edir. Bazar ertəsi günü Horizon2020 proqramı çərçivəsində Danimarka dövlət-özəl konsorsiumuna 7 milyon EUR subsidiya ayrıldı: biotexnologiya şirkətləri ExpreS2ion Biotexnologiyalar və AdaptVac. Konsorsium 12 ay ərzində peyvənd üçün I / IIa mərhələli klinik sınaq başlatmaq niyyətindədir. Ən erkən vaksinlər yaza qədər preklinik mərhələdə olmasına baxmayaraq, peyvəndin təhlükəsiz və effektiv olmasını təmin etmək üçün tənzimləyicilərin, ehtimal ki, bir ilə iki il arasında insan müayinəsindən keçməsi lazımdır. Təsdiqləndikdən sonra şirkətlər peyvəndi kommersiya miqyasında istehsal etməyə və yaymağa başlaya bilər, bu da uzun müddət çəkir. Xülasə, dünya təsdiqlənmiş Covid-19 peyvəndi yalnız 2121-ci illərin ortalarında görür. Bununla birlikdə, peyvəndin yalnız qurtuluş olmadığı ortaya çıxır. Bir çox şirkət yeni virus əleyhinə dərmanlar hazırlamağı və ya yeni virusa qarşı mübarizə aparmaq üçün mövcud təcrübi dərmanları uyğunlaşdırmağı gözləyir. Bu çətin bir işdir, çünki bakteriyalardan fərqli olaraq, viruslar öz hüceyrələrimizdə gizlənir. Bu o deməkdir ki, virusu dayandıran dərmanlar yan təsirlərə səbəb ola biləcək hüceyrələrimizə daha çox təsir edir. Süni intellekt vasitəsi ilə dərman istehsal edən Parisin İktos şirkəti Amerikanın SRI International kimyəvi şirkəti ilə əməkdaşlığa başladı. Əməkdaşlığın məqsədi Covid19 və digər növ virusların müalicəsi üçün yeni antiviral dərmanlar hazırlamaqdır. Avstriyanın biotexnologiya şirkəti Apeiron, fevral ayının sonunda Covid-19-a qarşı bir dərman dərmanının II pilot kliniki sınaqlarına başladı. Zülal dərmanı, kəskin ağciyər zədələnməsinin müalicəsində Faza I və II tədqiqatlarını tamamlamış və ağciyər işğalı zamanı koronavirusun bağladığı zülalları təqlid edərək işləməsi gözlənilir. Covid-19 müalicəsində təsdiqlənmiş antiviral dərmanların istifadəsini dəyişdirməyə yönəlmiş bir çox layihə də mövcuddur. Dərmanın təhlükəsizliyi onsuz da məlumdur və bazara daha sürətli çata bilər. Göttingen və Almaniyanın Almaniyadakı tədqiqatçıları hal-hazırda Yaponiyada pankreatitin müalicəsi üçün təsdiqlənmiş bir dərman - kamostat mesilatın potensialını araşdırırlar. http: //www.e-manus.pl/ BioNTech, moderna, curevac, covid-19, coronavirus, vaccine: 20200320AD BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi,  On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details. Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year. All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies. The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer. Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage. Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months. While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021. However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects. The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis. http://www.e-manus.pl/

: Data Publikacji.: 19-11-24